Shenzhen Synthetica Pioneering Co., Ltd. (Synthetica), a biotech startup focused on synthetic biology for creating novel bacterial therapeutics, has recently completed a Series A funding round. The investment was led by Boehringer Ingelheim Venture Fund and Temasek, with additional contributions from Lenovo Capital, Fosun Health Capital, and ATLATL Summer Fund.

深圳Synthetica创业有限公司（Synthetica）是一家专注于合成生物学以创造新型细菌疗法的生物技术初创公司，最近完成了一轮a系列融资。这项投资由勃林格殷格翰风险基金和淡马锡牵头，联想资本、复星健康资本和ATLATL夏季基金提供了额外资金。

The funds will be used to expedite the clinical trials of Synthetica's oncolytic bacterial therapies.Established in 2023 and based in Shenzhen, China, Synthetica specializes in genetic circuit engineering to precisely control genes and payloads for therapeutic purposes. The company is currently concentrating on developing oncolytic bacterial therapies for the treatment of solid tumors.

这些资金将用于加速Synthetica溶瘤细菌疗法的临床试验。Synthetica成立于2023年，总部位于中国深圳，专门从事基因电路工程，以精确控制用于治疗目的的基因和有效载荷。该公司目前专注于开发用于治疗实体瘤的溶瘤细菌疗法。

With advanced synthetic biology techniques and a strong grasp of biological mechanisms, Synthetica aims to create innovative, safe, and minimally invasive treatments for cancer.Synthetica’s CEO, Yingke He, expressed, “This funding represents a crucial development for our company as we advance cancer treatment.

凭借先进的合成生物学技术和对生物学机制的深刻理解，Synthetica旨在为癌症创造创新，安全和微创的治疗方法。Synthetica首席执行官何英科表示：“随着我们推进癌症治疗，这笔资金代表了我们公司的一项关键发展。

Our approach to synthetic biology and oncolytic bacteria provides new possibilities for targeted therapies. We appreciate the support from our technology partners and investors, and we are committed to making significant progress in cancer treatment to improve patients' lives worldwide.”Dr. Mia Hu, Investment Director at Boehringer Ingelheim Venture Fund, noted, “Boehringer Ingelheim Venture Fund is dedicated to supporting innovative therapeutics that address significant patient needs.

我们的合成生物学和溶瘤细菌方法为靶向治疗提供了新的可能性。我们感谢技术合作伙伴和投资者的支持，我们致力于在癌症治疗方面取得重大进展，以改善全球患者的生活。”。

Oncolytic bacterial therapy is a strategic priority for us, and we are excited to back Synthetica. Their expertise in synthetic biology and the development of bacterial therapies is promising, and we are eager to see their impact on treating so.

溶瘤细菌治疗是我们的战略重点，我们很高兴支持Synthetica。他们在合成生物学和细菌疗法发展方面的专业知识很有前景，我们渴望看到他们对治疗so的影响。